Clinical trials are research studies that test new treatments to see how well they work. MSKCC is one of the world’s largest clinical cancer research programs. There are four different types of clinical trials that are run at MSKCC.
Read More about Clinical Trials
Global Cancer Disparity Initiatives
Dr. Kingham has spent the past 15 years in developing countries training local medical professionals and delivering cancer care and treatment. In 2007, he co-founded Surgeons Overseas, a non-profit organization aimed at improving outcomes of surgery for patients in developing countries.
Read More about Global Initiatives
Hepatic Arterial Infusion (HAI) Chemotherapy
At Memorial Sloan Kettering Cancer Center, our team of surgeons, medical oncologists, interventional radiologists, radiation oncologists, and gastroenterologists work together for multi-disciplinary care of patients with colorectal liver metastases (CRLM).
Read More about HAI Chemotherapy
Radiologists assess subtle changes in contrast enhancement patterns on imaging to determine diagnosis and treatment response. Radiomics is an emerging field that attempts to derive quantitative information from enhancement patterns in imaging. We describe four projects to develop radiomic technologies with an eye toward the ultimate goal of precision therapy for hepatic and pancreatic tumors.
Read More about Imaging Markers
Improving Surgical Outcome
Our group prospectively records patient information into a large institutionally supported database for research purposes. We use these data to study the influence of clinical decision-making on patient outcome. Our goal is to constantly improve clinical management of cancer patients using a data-driven approach. These data inform clinical trial design and identify extant gaps in our understanding of disease.
Read More about Improving Outcome
Innovations in Surgical Technology
From virtual surgical planning, to image-guided surgery, to minimally invasive surgery, we continue to develop technologies with an eye toward the ultimate goal of precision therapy for hepatic and pancreatic tumors.
Read More about Innovations
Our HPB service has spearheaded many genetic and epigenetic studies to identify markers that are diagnostic and/or prognostic for patients with HPB cancers. Given our high surgical volume, we are uniquely poised to study these rare cancers.
Read More about Molecular Markers